Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines

August 17, 2011

ROCHESTER, Minn. -- Mayo Clinic has received investigational new drug approval (http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/default.htm) from the Food and Drug Administration (http://www.fda.gov/) for two new cancer vaccines that mobilize the body's defense mechanisms to destroy malignant cells. The vaccines are among the first aimed at preventing cancer recurrence. The approval clears the way for Phase I clinical trials with women treated for ovarian or breast cancer.

VIDEO ALERT: Additional audio and video resources, including comments by Dr. Keith Knutson are available at the Mayo Clinic News Blog (http://dev.newsblog.mayoclinic.org/2011/08/17/mayo-clinic-studies-cancer-vaccines/).

"People who've had cancer are at high risk for relapse, and later rounds of treatment can become more difficult," says Mayo Clinic immunologist Keith Knutson, Ph.D., (http://mayoresearch.mayo.edu/mayo/research/staff/Knutson_KL.cfm) who developed the vaccines with colleagues at Mayo Clinic. While most cancer vaccines to date have been developed to fight patients' tumors, Knutson's group is interested in immunizing patients immediately after therapy, when they're healthy, to protect against relapse.

One new vaccine targets a protein that exists in abundance in breast and ovarian cancer cells. Containing fragments of the folate receptor alpha protein, the vaccine teaches the body's immune system to detect and eliminate diseased cells. Because the protein is typical of nearly all breast and ovarian tumors, the vaccine is the first that may be applicable to the majority of patients, instead of sub-populations with distinct types of cancer.

"I'm quite optimistic that if we can combine early detection, effective conventional therapies and vaccination, we can reduce recurrence and long-term morbidity associated with breast and ovarian cancer," Knutson says. Ultimately, the vaccine may be useful as a preventive strategy for all women.

The second vaccine to receive FDA approval is designed to be administered after breast cancer patients receive conventional chemotherapy. It targets the highly aggressive Her2/neu molecule, a protein that promotes the growth of cancer cells.

"One of the greatest fears for women who've been treated for breast cancer is that the cancer will return," Knutson says. "Our hope is that the vaccine will boost the cancer-fighting capabilities of the immune system and will be a leg up on this aggressive cancer after conventional treatment is complete."
-end-
About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.com and www.mayoclinic.org/news.

Contact:
Joe Dangor
507-284-5005 (days)
507-284-2511 (evenings)

Mayo Clinic

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.